This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Landewé RB (2003) The benefits of early treatment in rheumatoid arthritis: confounding by indication, and the issue of timing. Arthritis Rheum 48: 1–5
Egsmose C et al. (1995) Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. J Rheumatol 22: 2208–2213
van der Heide A et al. (1996) The effectiveness of early treatment with “second-line” antirheumatic drugs. A randomized, controlled trial. Ann Intern Med 124: 699–707
van Aken J et al. (2004) Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis. Ann Rheum Dis 63: 274–279
Bukhari MA et al. (2003) Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. Arthritis Rheum 48: 46–53
Boers M et al. (1997) Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350: 309–318
Landewé RB et al. (2002) COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 46: 347–356
Puolakka K et al. (2005) Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum 52: 36–41
Grigor C et al. (2004) Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364: 263–269
van Gaalen FA et al. (2004) Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 50: 709–715
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Huizinga, T., Landewé, R. Early aggressive therapy in rheumatoid arthritis: a 'window of opportunity'?. Nat Rev Rheumatol 1, 2–3 (2005). https://doi.org/10.1038/ncprheum0015
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncprheum0015
This article is cited by
-
A 9 mRNAs-based diagnostic signature for rheumatoid arthritis by integrating bioinformatic analysis and machine-learning
Journal of Orthopaedic Surgery and Research (2021)
-
Comparative effectiveness research with administrative health data in rheumatoid arthritis
Nature Reviews Rheumatology (2016)
-
Visualizing arthritic inflammation and therapeutic response by fluorine-19 magnetic resonance imaging (19F MRI)
Journal of Inflammation (2012)
-
Looking through the ‘window of opportunity’: is there a new paradigm of podiatry care on the horizon in earlyrheumatoid arthritis?
Journal of Foot and Ankle Research (2010)
-
Antibodies to Citrullinated Vimentin are a Specific and Sensitive Marker for the Diagnosis of Rheumatoid Arthritis
Clinical Reviews in Allergy & Immunology (2008)